Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Life Science VC (Venture Capital) Funds in Switzerland in September 2025

Last updated: Sep 2025 A list of 50 VC (Venture Capital) funds that invest in Life science startups based in Switzerland. We rank investors based on the number of investments they made in Life science companies from Switzerland. We update this investor list every month.

Top 50 Life Science VC (Venture Capital) Funds in Switzerland in September 2025

Investor	Life Science Switzerland investments
Zürcher Kantonal Bank	6
Foundation for Innovation and Technology (FIT)	4
Eclosion SA	4
Omega Funds	2
Sunstone Life Science Ventures	2
Verve Ventures	2
SOSV	2
VINCI CAPITAL	2
Rheingau Founders	2
FAST — by GETTYLAB	2
Kinled Holding	2
EQT Life Sciences	2
EFI Lake Geneva Ventures	2
Versant Ventures	2
BlueOcean Ventures	2
Fongit Seed Invest	2
BioMedPartners	2
Lichtsteiner Foundation	2
HTGF (High-Tech Gruenderfonds)	2
Privilège Ventures	1
Novo Holdings	1
Pivotal bioVenture Partners	1
NEST pension fund	1
Primal Capital	1
VI Partners	1
NEXT VENTŪRES	1
Quan Capital	1
Blue Owl	1
Qiming Venture Partners	1
RTW Investments	1
Pfizer	1
MedHoldings	1
UZH Life Sciences Fund	1
Pfizer Venture Investments	1
Bruker	1
TiVentures	1
M Ventures	1
SICTIC	1
The Helm	1
OCCIDENT	1
Acequia Capital (AceCap)	1
Recipharm Venture Fund	1
RH Capital	1
JFG Life Sciences Foundation	1
S2S Ventures	1
Heritage Capital	1
Medicxi	1
Indaco Venture Partners	1
Think.Health	1
OrbiMed	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Zürcher Kantonalbank is an independent, incorporated public-law institution is its public service mandate. Enshrined in law, it governs the bank's economic, social, and environmental commitment.

Investment focus

Health Care, Medical Device, Biotechnology
Seed, Series A, Funding Round
Switzerland, Japan, Spain

Portfolio highlights

askEarth — We are your experts in satellite imagery (Earth Observation) and large language models (LLMs)
EarlySight — EarlySight start-up company is founded in order to accelerate the development and to bring the technology to clinics.
Polypeptide Group — The PolyPeptide Group is a contract manufacturing organization for peptides and peptide related molecules. A global presence throughout the world assures our clients a reliable supply with the necessary capacity for an uninterrupted service.The Group is one of the world’s largest independent contract manufacturers of therapeutic peptides forthe cosmetic, pharmaceutical and veterinary markets employing more than 450 people in six manufacturing sites located in France, India, Scandinavia and the USA.PolyPeptide Group is privately-held organization that manufactures over one third of all approved peptide drug substances (22 of 62 approved products worldwide) accounting for over 25% of the sales of outsourced peptide therapeutics worldwide.

The Foundation for Technology Innovation gives financial assistance to creative and technological projects at various phases of development. FIT funds projects in energy and the environment, information and digital technology, life sciences and health, precision industries, and nutrition and agriculture.

Investment focus

Health Care, Biotechnology, Information Technology
Debt Financing, Grant, Seed
Switzerland, France

Portfolio highlights

INERGIO — This EPFL spin-off is developing faster, portable energy units that offer ten times the power at half the weight of current technology. Founder Mahmoud Hadad’s fuel cell innovation, which uses standard butane or propane that’s safe and available worldwide, offers high autonomy. INERGIO’s fuel cell geometry allows unlimited scaling, making thetechnology suitable for applications ranging from charging consumer electronics to auxiliary power for drones to automobile fuel cells. The team has a working prototype and is looking to have its minimal viable product by summer 2020 to start the pilot project with potential partners and customers.
Brightank — Catalyzing your Decarbonization. Brightank accelerates decarbonization with ammonia cracking catalysts, turning ammonia into fuel for heavy transport, hydrogen supply, and power. EPFL spin-off
DigeHealth — DigeHealth's approach to monitoring gut health using bowel noises and body measurements could provide some really valuable insights into digestive well-being.

Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up

Investment focus

Biotechnology, Pharmaceutical, Health Care
Seed, Series C, Funding Round
Switzerland

Portfolio highlights

KYLYS — KYLYS is an innovative Swiss company based in Geneva founded in March 2017. KYLYS provides people and patients with highly effective and safe products based on biomolecules.
Genkyotex — Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
MPC Therapeutics — MPC Therapeutics develops a novel class of compounds with application in Immunotherapy and Metabolic diseases

We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases.
Alleviant Medical — Interventional therapy for congestive heart failure
Callio Therapeutics — Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits.

Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.

Investment focus

Biotechnology, Health Care, Medical
Funding Round, Series B, Series A
Denmark, Sweden, Switzerland

Portfolio highlights

Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.

Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.

Investment focus

Health Care, Software, Biotechnology
Series A, Seed, Series B
Switzerland, France, Germany

Portfolio highlights

Q.ANT — Q.ANT develops photonic processors for AI and high-performance computing, utilizing light for information processing. The company also produces quantum sensors offering ultra-high magnetic field sensitivity in a compact form factor. These products aim to enable more intelligent and sustainable systems across various sectors like data centers,aerospace, and medical technology.
Poppins — Mila merges music, technology, and neuroscience to reshape therapy into a musical experience. We create musical games for children based on neurologic music therapy methods. These games are designed to address learning dissabilities like dyslexia, providing a digital treatment at home and helping identify these conditions. Behind these games, weleverage data science and new technologies to interpret learning, language, and motor performance into a cognitive score. Our goal is to improve the process for patients receiving treatment and to reaching the vast undiagnosed majority.
EarlySight — EarlySight start-up company is founded in order to accelerate the development and to bring the technology to clinics.

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

MixRift — MIXRIFT - game developers specialized in Mixed Reality
unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

Vinci Capital is a leading Swiss private equity firm with over MCHF 200 under management. Since 1998 they have provided equity to over 30 Swiss technology and industrial companies to finance innovation, growth and succession-buyouts.Their investment team capitalizes on 40 years of cumulated experience in private equity and a solid operationalbackground in growth, turn-around, consolidation, IPOs and M&A situations.

Investment focus

Medical, Health Care, Biotechnology
Series A, Series B, Funding Round
Switzerland, Germany

Portfolio highlights

Anergis — Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne inSwitzerland.
SENSIMED — Sensimed designs, develops, and commercializes integrated micro-systems for medical devices. The company’s product portfolio includes SENSIMED Triggerfish, a product that offers an automated recoding of continuous ocular dimensional change over 24 hours. Sensimed is now focused on expanding the knowledge of how this individual data can best beused in the clinical setting to deliver customized treatment. The 24 hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis in an attempt to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment.Sensimed was founded by Matteo Leonardi and Sacha Cerboni in August 2003 and is based in Lausanne, Switzerland.
Beqom — beqom is a Total Compensation Management Software Solution focused exclusively on managing compensation & performance for HR & Sales.

Rheingau Founders is a Berlin&Munich based Venture Capital firm active since 2011. Focusing on pre-seed to Series A investments in Europe, predominantly B2B in the fields of Marketplaces, Software as a Service, InsurTech, and eHealth. Rheingau targets start-ups that have the potential to sustainably disrupt existing processes and value chains.Besides the financial investment, we offer strategic support through the mentorship of our partners.

Investment focus

Software, E-Commerce, Internet
Seed, Series A, Pre-Seed
Germany, United States, Poland

Portfolio highlights

MoleQlar — MoleQlar is a data and research-driven longevity company. It provides valuable information and offers consumers lab-tested nutritional supplements. The company focuses on functional medicine with optimized nutrition. Their product range includes Uthever NMN, Resveratrol, Betaine, Carnosine, and more. These products are aimed at lowering biologicalage and promoting health and longevity. MoleQlar also offers health tracking services. The company is certified in Germany and delivers its products EU-wide, including Switzerland.
Qualifyze — Qualifyze (former ChemSquare) was founded out of the Technical University of Darmstadt in September 2017. Today, we are based in Frankfurt am Main, the heart of Germany’s pharmaceutical cluster, where the leading life science companies are based. Our team consists of 16 people with diverse backgrounds and areas of expertise in business,engineering, and technology as well as several strategic partners from the pharma, food and cosmetics industry.
Akhetonics — Creating the first all-optical RISC Processor

Backing engineers building awe, wonder, speed.

Investment focus

Software, Biotechnology, Health Care
Pre-Seed, Seed, Funding Round
United States, United Kingdom, France

Portfolio highlights

Modelwise — Automated functional safety analysis via drag & drop. Seamless Integration. Faster Analyses. Zero Defects. More Savings.
Fluent Metal — Fluent Metal is a company that makes metal 3D printing economical, efficient, and safe.
Integrated Reasoning — Integrated Reasoning builds computer hardware to efficiently solve optimization problems. We're making faster and cheaper to solve problems like scheduling airline pilots or packing boxes into trucks.

Kinled was founded in 1980 to retain the investment assets of the Aisher family.In 1990, the investment focus shifted to a portfolio of early stage investments applying Kinled’s company development experience alongside the endurance and passion of family owned investments together with the strategic focus of venture capitalists.Since then,Kinled has taken 8 companies to public markets and many more to successful trade sales at significant multiples.

Investment focus

Biotechnology, Health Care, Financial Services
Seed, Funding Round, Series A
United Kingdom, United States, Switzerland

Portfolio highlights

Xapien — Xapien delivers automated insight reports on companies and individuals in minutes, so you can make informed business decisions quickly and with confidence.
OneTrust — OneTrust is a provider of privacy management and marketing compliance technology that helps organizations comply with global regulations. It automates privacy impact assessments and data inventory mapping, enforces risk remediation actions, and triggers recurring audits for continuous compliance monitoring across customer, employee, and vendor datatransfers. Its web-based software can be accessed on any device and provides a single place for a private office to collaborate with business groups, vendors, and trusted advisors managing privacy risks. The result is the ability to demonstrate privacy by design and ongoing compliance with policies, data privacy laws (GDPR, BCR, Privacy Shield), and other privacy frameworks (HITECH, ISO, GAPP, APEC).The company was founded in 2016 and is headquartered in Atlanta, Georgia.
Connect Earth — Connect Earth is an environmental data company that builds the infrastructure for climate-conscious products by aggregating and standardising environmental data and making it available through developer-first toolkits. The core product is an API solution that calculates the carbon impact of spend-based financial transactions of consumers and companies.

Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, The Netherlands, Switzerland

Portfolio highlights

Cyted — Cyted focuses on providing digital diagnostic infrastructure to drive the earlier detection of disease. Our technologies use AI and novel biomarkers to improve patient outcomes.
Perfuze — Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. Perfuze is located within Galway City in the West of Ireland. The founders have over 30 years combined medtech experience within start-up and large corporations.Perfuze is developing innovative medical technology to treat acute ischemic stroke.Perfuze is developing innovative cathetertechnology to treat acute ischemic stroke. Their technology is intended to provide superior clinical outcomes in shorter procedural times; resulting in safe, cost-effective therapy. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. The founders have over 30 years combined medtech experience within start-up and large corporations. Perfuze is currently located in the Business Innovation Centre on the campus of the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway.
Avidicure — Avidicure is developing dual agonistic avidity-engineered multifunctional antibodies, AVC-Boosters, as monotherapy for treatment of cancer

EFI Lake Geneva Ventures is a seed and early-stage investment strategy based in Geneva, Switzerland. Founded in 2020, our mission is to foster innovation by investing at an early stage in fast-growing innovative Swiss companies in Technology, Life Sciences and Medtech.

Investment focus

Health Care, Medical, Life Science
Seed, Pre-Seed, Series B
Switzerland, Germany

Portfolio highlights

EBAMed — EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware andsoftware components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
Hylomorph — Hylomorph is a clinical-stage medical device company developing innovative materials designed to transform the biocompatibility of implantable medical devices.
Annaida Technologies — Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies.

Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Switzerland, Canada

Portfolio highlights

Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
Helicore Biopharma — Helicore Biopharma is at the forefront of developing cutting-edge treatments for obesity and related disorders.
Kriya Therapeutics — Kriya is a biopharmaceutical company developing gene therapy to address common diseases that impact millions of people worldwide. Learn more.

BlueOcean Ventures SA provides capital, operational and company development advisory support (mentoring, company management, divestment experience, network, negotiation support) to entrepreneurs in Switzerland. BlueOcean Ventures is based in Geneva, Switzerland.

Investment focus

Health Care, Medical, Biotechnology
Series A, Seed, Series B
Switzerland, India, France

Portfolio highlights

nPloy — Simply set your filters and get matched with your dream job! Let top employers apply for you & connect with them via chat or a video call.
CyanoGuard AG — Our award-winning cyanide testing and optimizing solution is ideal for the mining, food, and medical field. It's easy to use, digital and offers real-time data.
99RetailStreet — 99RetailStreet is an eCommerce Cloudplatform for the unorganized Retail business in the developing countries. Our ecosystem targets Retailers, Distributors, and Manufacturers. 99RetailStreet provides POS solutions to Retailers, Real-Time Analytics to Manufacturers and Distributors

Fongit Seed Invest (FSI) is the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital.

Investment focus

Health Care, Medical, Biotechnology
Seed, Series A, Series B
Switzerland

Portfolio highlights

EBAMed — EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware andsoftware components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
Gmelius — Gmelius is the world's first 360 email collaboration platform designed for Gmail and your company's daily apps. Join the async movement!
Annaida Technologies — Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies.

BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
Switzerland, Germany, France

Portfolio highlights

ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
TOLREMO therapeutics — TOLREMO therapeutics is striving to prevent the development of cancer therapy resistance through its proprietary drug discovery and development platform. Learn more about us.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

Boosting health pioneers. We invest in early stage start-ups in different sectors: medtech, life science, biotech, mental health, public health, well-being.

Investment focus

Medical, Health Care, Biotechnology
Seed, Series A
Switzerland

Portfolio highlights

Testmate Health — 2 in 1 urine test with immediate results for Chlamydia trachomatis and Neisseria gonorrhoeae. Results within minutes & 100% anonymous.
Limula — Limula provides a unique platform technology enabling scale out of cell therapy production. By bringing manufacturing closer to the patients, our solution will broaden access to these highly personalised treatments. Our patented solution is composed of an automation unit and single use kits, allowing healthcare providers to safely manufacture CGTin a decentralized manner. We support companies at all stages of the cell therapy life cycle, from R&D to routine production.
SEITO Biologics — SEITO Biologics AG develops innovative IL-2 immunotherapies that preferentially activate T regulatory (Treg) cells, while sparing cytotoxic effector immune cells.

High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.

Investment focus

Software, Biotechnology, Information Technology
Seed, Series A, Funding Round
Germany, Switzerland, United States

Portfolio highlights

Mevaldi — Mevaldi is a biotechnology company. They investigate, select, and bring to market new technologies in the field of bio-based chemicals. They provide a revolutionary approach that integrates the large-scale biological conversion of sugars to low-cost mevalonolactone with a further cascade of thermo-catalytic conversions to various bio-monomers.
TrustNXT — TrustNXT is the trust authority for digital media, providing innovative software solutions to safeguard digital photos and videos from manipulation. Our technology verifies the origin, content, and metadata of digital media, while advanced forensic tools empower users to assess the trustworthiness of visual content. With a mission to protectauthenticity and foster safer digital environments, TrustNXT is committed to combating fraud and ensuring the integrity of digital media in today's digital world.
Pactos — Pactos streamlines and digitizes processes to enable large and medium-sized businesses to effectively and centrally procure and manage their contingent labor.

Where Entrepreneurs Thrive Rooted in reality, reaching for the extraordinary over five decades of combined investment experience Where Entrepreneurs Thrive Rooted in reality, reaching for the extraordinary Authentic, dedicated, disciplined, and goal-oriented, our team drives meaningful and lasting success About Team

Investment focus

Health Care, Hardware, Software
Seed, Series A, Funding Round
Switzerland, France

Portfolio highlights

Wyth — Wyth creates private digital spaces for virtual and hybrid audiences. With our fully customizable platform organizations can build a seamless experience and an online home for their communities to connect, learn, work, share and play without ever leaving Wyth. We give our customers full control over their brand experience, data ownership andbusiness relationships.
Smeetz — Smeetz is the future of a unified, data-driven and dynamic pricing-oriented commerce for attractions and cultural venues.
Avelo — Our mission is to save lives by bringing fast and actionable infectious disease diagnosis closer to the patient. Avelo's solution is a breath collection device. It works with existing molecular tests to detect multiple respiratory tract infections causing pneumonia

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Denmark, United Kingdom

Portfolio highlights

Mission Bio — We offer the only multi-omics single-cell technology solution that simultaneously detects SNV, CNV, and protein data from the same cell. Find out more.
Sparrow Quantum — Sparrow Quantum, a global leader in quantum photonic chip technology. Explore innovative solutions driving advancements in quantum computing, communication, and beyond. Stay ahead with cutting-edge technologies shaping the future.
Reunion Neuroscience — Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depressionand other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.

Pivotal Life Sciences specializes in providing capital to innovative companies developing therapeutic products to address major unmet medical needs.

Investment focus

Biotechnology, Pharmaceutical, Health Care
Series B, Series C, Series A
United States, China, Canada

Portfolio highlights

Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases.
Zenas BioPharma — Enabling patients with autoimmune diseases to reimagine life

For more than 35 years, Nest, as the first ecological and ethical pension fund in Switzerland, has remained true to its guiding principle: the optimal provision for the companies affiliated with us and their employees.

Investment focus

Health Care, Biotechnology, Medical
Seed, Series A
Switzerland

Portfolio highlights

Piomic — There are about 50 million reported cases of patients suffering from hard-to-heal wounds, which has created a severe cost burden on global healthcare systems.The COMS® One Therapy System is a portable, hand-held device which incorporates the technologies for optical and magnetic stimulation, intended to promote wound healing in chronic leg andfoot ulcers.The pivotal clinical study showed that the treatment is safe, leads to accelerated wound closure, overall reduced pain and increased quality of life. The easy-to-use, single button operated device integrates smoothly into the patient’s healing journey with usage in stationary and ambulant facilities but also in patient’s home.By developing a therapy which is safe and effective we hope to set a better future for patients in need.
Comphya — CaverSTIM is a novel implantable device able to restore natural penile erection by neuromodulation.
Nagi Bioscience — Enabling small organisms testing to any lab. Unleash unique datapoints efficiently at a high-throughput rate.

Primal Capital is an early stage and growth investor in Web3 and emerging technology companies. Our current portfolio consists of 50+ investments in Web3 & blockchain applications focused on consumer and enterprise adoption.

Investment focus

Blockchain, Information Technology, Artificial Intelligence
Seed, Pre-Seed, Series A
United States, United Kingdom, Switzerland

Portfolio highlights

Transak — Transak offers a simple integration to allow your users to buy more than 100+ cryptocurrencies with credit/debit cards, or bank transfers in more than 120+ countries.
Agents World — Agents World operates as an web3 AI firm.
Ooga Booga — Multichain Liquidity Aggregator

VI Partners are Venture Capitalists successfully financing outstanding teams and innovations in the Healthcare and Technology space since 20 years.

Investment focus

Health Care, Biotechnology, Medical Device
Series A, Series B, Series C
Switzerland, Germany, United States

Portfolio highlights

Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
LeaseTeq — LeaseTeq bietet Privat- sowie Unternehmenskunden das erste komplett digitale Leasingangebot.
Unique — Try Unique Finance GPT to increase productivity by automating manual workload through AI and ChatGPT solutions.

NEXT VENTŪRES is a venture capital firm that invests in the sports, fitness, health, and wellness markets. With established expertise and deep connections in these markets as well as proven financial track records, the NEXT VENTŪRES team is well positioned to create significant value for their investors and their portfolio companies.The firm wasestablished in 2018 and is based in San Francisco, CA

Investment focus

Health Care, Wellness, Medical
Seed, Series A, Series B
United States, Canada, Finland

Portfolio highlights

Pair Team — Pair Team is on a mission to build the primary care infrastructure for America’s most vulnerable communities.They are the first tech-enabled care team that empowers safety-net primary care systems and the Medicaid & Medicare patients they serve. They act as an extension of the clinical staff to provide a personalized, high-touch careexperience while addressing patients' barriers to care such as lack of transportation, housing/food insecurity, and mobile phone access. Internally, they are building a unique care delivery platform to ensure clinical best practices, integrate care with community-based organizations, and automate administrative work so that clinicians can focus on time with our patients.
Eternal — Eternal offers lifetime athletes an expert team of health and performance experts to help them stay active in the sports they like for as long as possible.
Eternal — With a mission to keep athletes active and thriving in their chosen sports for as long as possible, Eternal provides members with a holistic understanding of their health, fitness, and benchmarks for key markers of the aging process along with guidance from high-performance care teams to support every stage of an athlete’s journey.

Quan Capital Management is a venture capital firm that invests in healthcare, pharmaceutical, and biotech startups. The Company is based in China, but makes investments globally.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series B, Series A, Funding Round
United States, China, Hong Kong

Portfolio highlights

Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases.
Zenas BioPharma — Enabling patients with autoimmune diseases to reimagine life
Avenzo Therapeutics — Developing the next generation of oncology therapies for patients.

Blue Owl is a leading asset management firm offering alternative investment solutions in private credit, GP stakes, and real assets.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Debt Financing, Post-IPO Equity, Series B
United States, United Kingdom, Canada

Portfolio highlights

Neuron23 — Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
Baker Tilly — Since they formed in 1987, they have grown to a top ten practice with over 100 employees in Ireland. they are known for building long term, personal relationships with their clients. they know that their success is measured by their clients’ success, if they are achieving their goals they know they’re doing their job.As a top ten firm, theyoffer access to service line specialists, sector specific experience and can leverage true international expertise through their membership of the Baker Tilly International network. they offer solutions.Their client’s requirements are their strategic drivers. They keep us striving to do more, to go further, to realise the very best outcome for their business challenges. In turn, they deliver hard-working solutions, innovative strategies and expert advice, borne of industry experience and rigorous thought.They give advice they believe in.
Juniper Square — Juniper Square is the leading provider of investment management software and solutions for real estate and private equity fundraising, investor reporting, and more.

Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.

Investment focus

Health Care, Biotechnology, Medical
Series B, Series A, Series C
China, United States, Hong Kong

Portfolio highlights

Yanshengchao — Room A204-1, Floor 2, Building 2, Yard 9, Yike Road Life Science Park, Changping District Beijing China
Minghui Pharmaceutical — Minghui Pharmaceutical is a biopharmaceutical business that specializes in immunology and oncology medicines for unmet needs.
Huimei Technology — Huimei Technology is a National high-tech enterprise that offers medical artificial intelligence solutions.

We invest in biotech and medtech innovation across the full lifecycle from company creation to venture capital, alternative financing, and public companies.

Investment focus

Biotechnology, Health Care, Therapeutics
Post-IPO Equity, Series B, Series C
United States, Switzerland, China

Portfolio highlights

Belite Bio — Belite Bio focused on first-in-class therapeutics targeting untreatable inherited orphan diseases and age-related metabolic diseases, including atrophic age-related macular degeneration, stargardt disease, and nonalcoholic steatohepatitis. They develop anti-RBP4 therapies to treat age-related metabolic diseases, including macular degeneration,liver disease, and diabetes. Their technology platform effectively reduces circulating levels of RBP4, a vitamin A transporter protein linked to the development of aging metabolic diseases, including dry age-related macular degeneration, liver disease, and diabetes.
Umoja Biopharma — Pioneering immunotherapy by reprogramming T cells in vivo to target cancer cells.
Allurion Technologies — Allurion Technologies is developing a medical device for weight loss that can be delivered and removed without surgery or endoscopy.

Pfizer provides access to safe and effective and affordable medicines and health care services. They have a portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and they have an industry-leading pipeline of promising new products that havethe potential to challenge some of the most feared diseases of their time, like Alzheimer's disease and cancer.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Post-IPO Equity, Series A, Corporate Round
United States, Israel, France

Portfolio highlights

CellCentric — CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.
AgomAb Therapeutics — AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
EvolveImmune Therapeutics — EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases.

MedHoldings operates as a venture capital and private equity firm. MedHoldings focuses primarily on development and late-stage medtech ventures in Switzerland, Europe, and emerging markets. The company conducts its business in Switzerland.

Investment focus

Medical, Health Care, Life Science
Series A
Switzerland

Portfolio highlights

Abionic — Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses these highly advanced technologies to provide the medical profession with a novel diagnostic tool designed to give patients personal allergyprofiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.Abionic SA is a certified ISO 9001/13485 company, including research, development and commercialization of in vitro diagnostic devices for allergies detection. The standard ISO 13485 specifies requirements for a quality management system where an organization has to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements.Abionic SA is a privately owned high-tech company and is strongly supported by the Swiss Federal Institute of Technology of Lausanne (EPFL), The Canton of Vaud and Venturelab.Abionic was founded by former scientists from the biomedical optics laboratory (LOB) at EPFL. Its headquarters are located in Lausanne, Switzerland.Abionic appreciates the support it has received from:

The UZH Life Sciences Fund involves two equal partners: the UZH Foundation and the Novartis Venture Fund. It seeks donations from private individuals, foundations and companies for the strategic priorities of the University of Zurich.

Investment focus

Health Care, Biotechnology, Medical Device
Funding Round, Seed, Convertible Note
Switzerland

Portfolio highlights

Occlufit — Occlufit is an occluder device that conforms to complex geometries and provides immediate sealing of cardiovascular defects.
Navignostics — Navignostics combines highly multiplex tumor imaging with advanced data analytics for personalized cancer treatments.
ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.

Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’spipeline and shape the future of its industry.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, United Kingdom, Switzerland

Portfolio highlights

TRex Bio — TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis.
Normunity — We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.
TRIMTECH Therapeutics — Transformative treatments for CNS and inflammatory disorders by selectively destroying disease-causing protein aggregates

Bruker Corporation is a provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis.

Investment focus

Biotechnology, Medical, Health Care
Series A, Funding Round, Seed
United States, Switzerland

Portfolio highlights

KIYATEC — Kiyatec is a functional precision oncology company that measures the response of individual patient live cancer cells with its innovative 3D cell culture technology platform. Kiyatec works with leading biopharmaceutical companies to unlock response dynamics for investigational drug candidates for use in solid tumors.
Terrain Bio — Terrain Bio helps RNA therapeutics companies design and build better RNA, faster. Leveraging the latest innovations in protein and RNA design and the deep expertise of its scientific cofounders, Terrain brings unparalleled speed and quality to RNA manufacturing.
Mercy BioAnalytics — We are making early stage cancer 100,000x easier to find using extracellular vesicles found in blood, specific to their parent cells.

TiVenture is a seed investment fund owned by the Fondazione Centenario Banca Stato that invests in early stage companies with innovative technologies and high growth potential, principally in southern Switzerland. TiVenture is actively looking and ready to support exceptional founders and entrepreneurs developing scalable products for the globalmarket. TiVenture has a diversified portfolio of companies and is mainly active in the life science, medical, high-tech and IT sectors.

Investment focus

Software, Analytics, Renewable Energy
Seed, Series A, Funding Round
Switzerland, Italy, United States

Portfolio highlights

Hoxell — Hoxell is an intuitive and easy-to-use integrated platform that digitizes and streamlines all hospitality operations.
Hive Power — Hive Power provides a SaaS platform to optimise your existing electrical distribution grid, both from the technical and economic points of view.
Gaia Turbine — Gaia Turbine SA - High-Performance Hydroelectric Turbine for micro and mini power plants

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, United Kingdom, Switzerland

Portfolio highlights

Biolinq — Introducing a revolutionary platform for metabolic health.
ChEmpower — ChEmpower is an advanced materials company that develops chemically reactive, abrasive-free planarization pads to improve chip yields and sustainability in semiconductor manufacturing.
Corvic AI — Corvic AI is pioneering a new era of Data-Centric AI Cognitive Infrastructure by transforming raw enterprise data into AI-ready intelligence.

Swiss ICT Investor Club (SICTIC) connects smart money investors to Swiss seed and early-stage tech startups.

Investment focus

Software, Artificial Intelligence, Information Technology
Seed, Pre-Seed, Funding Round
Switzerland, Germany, United Kingdom

Portfolio highlights

Pelt8 — Pelt8 enables climate action through the platform with scalable processes and controls to collect sustainability-related data in an easy and traceable way.
Nextesy — Nextesy is a pioneering start-up that uses AI to simplify and automate important business processes, allowing businesses to alleviate the strain of repetitive manual procedures while increasing operational efficiency and scalability.
Insurteam — Insurteam provides the benefits of its technology to all insurance companies that service the travel and leisure sector.

The Helm is the place to discover, shop, and fund female-identifying entrepreneurs.

Investment focus

Health Care, Communities, E-Commerce
Seed, Funding Round, Series A
United States, Switzerland

Portfolio highlights

Sway — Sway offers regenerative design solutions for plastic pollution using seaweed to create compostable replacements for single-use plastics. The company was co-founded by Julia Marsh, Matt Mayes, and Leland Maschmeyer and is headquartered in San Francisco, California, United States.
Testmate Health — 2 in 1 urine test with immediate results for Chlamydia trachomatis and Neisseria gonorrhoeae. Results within minutes & 100% anonymous.
itselectric — Itselectric partners with city property owners to unlock access to untapped electricity supply while they earn passive income.

Occident is an international, privately held investment company based in Zug and Munich. Our goal is to manage our own wealth in a sustainable, meaningful manner seeking to make a positive contribution to society through our investments. Venture Capital is the focus of our investment activities. We see ourselves as a long-term oriented enabler forinnovative start-ups and visionary founders. As a complementary team of experts, we are fascinated by technologically sound topics (deep tech) from the life sciences, digital and high-tech sectors with the potential to decisively improve people's lives.

Investment focus

Health Care, Medical Device, Biotechnology
Series A, Series B, Series C
Germany, Switzerland, Slovenia

Portfolio highlights

ReCatalyst — REvolutionizing the way we make fuel cell CATALYSTs
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
Lunaphore — Lunaphore Technologies is a spatial biology company, building multiplex immunofluorescence & IHC solutions for discovery and immuno-oncology research

We are a leading early-stage investment platform. We are at the center of a global ecosystem that attracts and fuels the technical founders and product teams building the next wave of global businesses.

Investment focus

Software, Information Technology, Artificial Intelligence
Seed, Series A, Pre-Seed
United States, United Kingdom, France

Portfolio highlights

Deta — The cloud for doers and dreamers
AnySignal — AnySignal was developed to reimagine how RF capabilities are delivered for the most difficult tasks around the globe. offers complete solutions for modern aircraft, satellites, and national security that span communications, radar, navigation, and RF sensing. Current solutions are overpriced, unimaginative, and provide little end-to-end capability.To shift this paradigm, they are bringing the appropriate talent, procedures, and technologies together. They are developing communications systems for satellites, launchers, space stations, and aircraft. They provide full-stack connectivity solutions that include software modems, hardware for use in flight and on the ground, data management software, ground station integration software, and vehicle telemetry software.
Harbinger — Founded by veterans of Canoo and Faraday Future, Harbinger is an automotive company that develops EV platforms optimized for medium-duty trucks and delivery vans.

Recipharm Venture Fund is part of Recipharm AB.

Investment focus

Biotechnology, Medical, Health Care
Series A, Funding Round
Sweden, Switzerland

Portfolio highlights

NewBiologix — NewBiologix operates as a technology innovation company, develops a proprietary and breakthroughDNA integration platform for the advanced engineering of human and mammaliancell lines.
Cinclus Pharma — A Swedish pharma company bringing relief to the world with the clinical stage drug candidate linaprazan glurate for gastric acid related diseases.

RH Capital a Rhia Ventures fund, is an impact-first venture capital firm that invests in early-stage startups with the potential to transform women's health and increase health equity.

Investment focus

Health Care, Biotechnology, Health Diagnostics
Funding Round
United States

Portfolio highlights

Eli — Eli empowers women to understand their body and the transitions it goes through every day, and across life. We develop a device that uses saliva to capture hormone fluctuations at home, and an app that gives women the information they want to own their health decisions.
Novocuff — Novocuff is a medical device firm that aims to improve pregnancy outcomes and reduce preterm deliveries caused by PPROM and cervical shortening.
Seven Starling — Seven Starling offers comprehensive online care for postpartum mental health. Take the free assessment to get started.

JFG Life Sciences Foundation is a non-profit foundation.

Investment focus

Biopharma, Health Care, Biotechnology
Seed
Switzerland

Portfolio highlights

Invasight — Invasight is a clinical biotech company that focused on revolutionizing cell invasion research. The company was founded in 2019 and is headquartered in Zurich, Switzerland.
NXI Therapeutics — NXI Therapeutics - Creating Tomorrow's Immunotherapies | The beginning of a new era of specificity and safety in the immunosuppressive therapy market

Students run the whole VC operation and are supported by a strong network of mentors. S2S is organized as a cross-campus initiative (ETH Zurich, EPFL, HSG, UZH) that fosters collaboration between different existing entrepreneurial student organizations.

Investment focus

Health Care, Information Technology, Software
Pre-Seed, Funding Round, Convertible Note
Switzerland, Germany

Portfolio highlights

Rrreefs — Our mission is to regenerate degraded coral reefs at global scale - restoring rich marine biodiversity for a healthy ocean.
Yuon Control — Yuon Control offers an advanced and predictive heating control system designed to optimize heating networks. It makes an effective contribution to CO2 reduction.
Cotierra — Biochar made from agricultural residues in the tropics can become a gamechanger for farmers and climate change mitigation

Heritage Bank

Investment focus

Biopharma, Life Science
Seed
Switzerland

Portfolio highlights

Lagosta — WHAT WE DO. At LAGOSTA, we take great care in sustainably farming the European spiny lobster, converting byproducts in unique highly valuable products and setting up a series of ecological programs. Accelerated depletion of wild stocks due to overfishing and

Medicxi is an investment firm that focuses on the life sciences sector. It was established in 2016 by the former Index Ventures life sciences team, who have been active for over 20 years and have significant experience in drug discovery and the development of therapeutics for unmet medical needs.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series A, Series B, Seed
United States, United Kingdom, The Netherlands

Portfolio highlights

Curevo — focused on a new generation of adjuvanted subunit vaccines Learn More Our Focus We're dedicated to developing non-mRNA vaccines for unmet medical needs Curevo Vaccine is a clinical-stage biotech company dedicated to developing next-generation non-mRNA vaccines. We focus on one need at a time, allowing us to bring effective and better-tolerated vaccines to market quickly
Rapt Therapeutics — RAPT Therapeutics is a clinical-stage biopharmaceutical company driven by our mission to treat inflammatory and immunologic diseases. Our cutting-edge science is fully focused on developing therapeutics that intelligently target key drivers of the immune system to transform the treatment of inflammatory and immunologic diseases, and improve and empower countless lives. Join us in our quest.
Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.

VENTURE We invest across all sectors with specific focus on technology and digital The largest independent more About Us Portfolio [...]

Investment focus

Biotechnology, Health Care, Life Science
Series A, Series B, Funding Round
Italy, Switzerland, United States

Portfolio highlights

Easy Rain — Easyrain provides innovative automotive safety solutions for OEMs, including virtual sensors (DAI) and aquaplaning prevention (AIS). Explore our cutting-edge technologies!
CamGraPhIC — Our platform supports the ever-increasing data traffic demand with high-performing and low-power consumption electro-optical engines.
Iama Therapeutics — At IAMA Therapeutics, we are constantly pushing the boundaries of neuroscience drug discovery to develop new medicines and make a difference in the lives of children suffering from brain disorders and their families. Our purpose is to provide a therapeutic solution to children suffering from neurological conditions and provide their families withthe support they need.

Think.Health invests as a boutique risk-taker in healthcare ventures. We continuously seek innovations and disruptive business models in digital healthcare, medical technologies and health service providers,

Investment focus

Health Care, Biotechnology, Medical Device
Seed, Series A, Series B
Germany, United States, Switzerland

Portfolio highlights

Robeaute — Redesigning the future of neurosurgery by creating the new standard device that will provide surgeons with seamless access to delicate areas of the brain parenchyma and with real-time data.
Inflammatix — Inflammatix develops rapid point of care diagnostic tests by reading the immune system, and resolves major clinical health challenges.
Sphingotec GmbH — Improving patient outcomes with innovative diagnostics for critical care: Actionable insights in real-time

Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, China, Israel

Portfolio highlights

CHARM Therapeutics — CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins.
Treeline Biosciences — Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions. The company was founded in 2021 and is headquartered in Stamford, CT.
Congruence Therapeutics — ABOUT US We are a drug discovery company that is uniquely harnessing the power of protein dynamics, biophysics, machine learning and computational chemistry. Our Science Traditional drug design is limited At Congruence,

Investors by industry

Artificial intelligence

Climate

Consumer

Community